RECODE THERAPEUTICS

recode-therapeutics-logo

ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dy... skinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

#SimilarOrganizations #People #Financial #Event #Website #More

RECODE THERAPEUTICS

Social Links:

Industry:
Biopharma Biotechnology Health Care Pharmaceutical Wellness

Founded:
2015-01-01

Address:
Dallas, Texas, United States

Country:
United States

Website Url:
http://www.recodetx.com

Total Employee:
51+

Status:
Active

Contact:
469-306-1618

Email Addresses:
info@recodetx.com

Total Funding:
282 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics Google Universal Analytics Nginx Microsoft Exchange Online Office 365 Mail Nginx 1.14


Similar Organizations

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

aztherapies-logo

AZTherapies

AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.

day-one-biopharmaceuticals-logo

Day One Biopharmaceuticals

Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.

eidos-therapeutics-logo

Eidos Therapeutics

Eidos Therapeutics is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients.

forma-therapeutics-logo

FORMA Therapeutics

FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.

homology-medicines-logo

Homology Medicines

Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.

lyra-therapeutics-logo

Lyra Therapeutics

Lyra Therapeutics is a clinical-stage company developing medicines to treat ear, nose, and throat diseases.

pliant-therapeutics-logo

Pliant Therapeutics

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.


Current Advisors List

not_available_image

Rana Al-Hallaq Board Member @ ReCode Therapeutics
Board_member
2021-10-01

helen-s-kim_image

Helen S. Kim Board Member @ ReCode Therapeutics
Board_member

not_available_image

David Lockhart Board Member @ ReCode Therapeutics
Board_member
2020-01-01

michael-torres_image

Michael Torres Board Member @ ReCode Therapeutics
Board_member

shehnaaz-suliman_image

Shehnaaz Suliman Board of Directors @ ReCode Therapeutics
Board_member
2022-06-29

peter-thompson_image

Peter Thompson Board Member @ ReCode Therapeutics
Board_member

not_available_image

Rakhshita Dhar Board of Directors @ ReCode Therapeutics
Board_member
2022-06-29

ed-hurwitz_image

Ed Hurwitz Board Member @ ReCode Therapeutics
Board_member

Current Employees Featured

daniel-siegwart_image

Daniel Siegwart
Daniel Siegwart Co-Founder @ ReCode Therapeutics
Co-Founder
2015-01-01

michael-torres_image

Michael Torres
Michael Torres Co-Founder and Vice President of R&D @ ReCode Therapeutics
Co-Founder and Vice President of R&D

not_available_image

David Lockhart
David Lockhart President and CEO @ ReCode Therapeutics
President and CEO

philip-thomas_image

Philip Thomas
Philip Thomas Co-Founder @ ReCode Therapeutics
Co-Founder
2015-12-01

angele-maki_image

Angele Maki
Angele Maki Senior Vice President and Head of Business Development @ ReCode Therapeutics
Senior Vice President and Head of Business Development
2021-08-01

not_available_image

Nicholas P. France
Nicholas P. France Senior Vice President of Clinical Development @ ReCode Therapeutics
Senior Vice President of Clinical Development
2021-01-01

shehnaaz-suliman_image

Shehnaaz Suliman
Shehnaaz Suliman CEO & Board Member @ ReCode Therapeutics
CEO & Board Member
2022-01-01

Founder


daniel-siegwart_image

Daniel Siegwart

michael-torres_image

Michael Torres

philip-thomas_image

Philip Thomas

Investors List

matrix-capital-management_image

Matrix Capital Management

Matrix Capital Management investment in Series B - ReCode Therapeutics

leaps-by-bayer_image

Leaps by Bayer

Leaps by Bayer investment in Series B - ReCode Therapeutics

amgen-ventures_image

Amgen Ventures

Amgen Ventures investment in Series B - ReCode Therapeutics

pfizer-venture-investments_image

Pfizer Venture Investments

Pfizer Venture Investments investment in Series B - ReCode Therapeutics

sanofi-genzyme-bioventures_image

Sanofi Ventures

Sanofi Ventures investment in Series B - ReCode Therapeutics

colt-ventures_image

Colt Ventures

Colt Ventures investment in Series B - ReCode Therapeutics

vida-ventures_image

Vida Ventures

Vida Ventures investment in Series B - ReCode Therapeutics

sanofi-genzyme-bioventures_image

Sanofi Ventures

Sanofi Ventures investment in Series B - ReCode Therapeutics

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series B - ReCode Therapeutics

pfizer-venture-investments_image

Pfizer Venture Investments

Pfizer Venture Investments investment in Series B - ReCode Therapeutics

Official Site Inspections

http://www.recodetx.com Semrush global rank: 3.74 M Semrush visits lastest month: 3.62 K

  • Host name: 141.193.213.20
  • IP address: 141.193.213.20
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "ReCode Therapeutics"

ReCode Therapeutics - Powering the future of genetic medicines …

ReCode is the first genetic medicines platform to enable highly targeted delivery to organs, tissues and cells beyond the liver. Our pipeline of rare disease therapeutics uses optimized …See details»

ReCode Therapeutics - Crunchbase Company Profile & Funding

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics. Its selective organ targeting (SORT) lipid nanoparticle (LNP) platform …See details»

ReCode Therapeutics - LinkedIn

At ReCode Therapeutics, we're reshaping the future of Cystic Fibrosis (CF) treatment with our SORT LNP platform. Our clinical-stage candidate, RCT2100, targets the root cause of CF, particularly...See details»

ReCode Announces Two Key Additions to Scientific Advisory Board

Oct 1, 2024 · ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the …See details»

Recode Therapeutics - Overview, News & Similar companies

Jun 13, 2024 · ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs …See details»

ReCode Therapeutics to Expand Next-Generation …

Jun 29, 2022 · ReCode Therapeutics is a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid...See details»

Cystic Fibrosis - ReCode Therapeutics

Using our SORT LNP platform, ReCode is targeting the underlying cause of the disease so that more people with CF may benefit. ReCode’s CFTR mRNA (RCT2100) is a clinical-stage candidate in development to treat the 10 percent …See details»

ReCode Therapeutics - VentureRadar

Website: https://recodetx.com Develops precision genetic medicines using a proprietary delivery platform for treatment of various genetic diseases, including cystic fibrosis and primary ciliary …See details»

ReCode Therapeutics Announces First Participants Dosed in a …

Feb 21, 2024 · Formulated using ReCode’s proprietary SORT LNP delivery platform, RCT2100 is an inhaled therapy designed to deliver CFTR mRNA to target cells and instruct them to make …See details»

ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study …

Jan 3, 2024 · ReCode has launched ThinkPCD.com, a program that provides genetic testing to PCD patients that qualify at no cost. Patients can enroll directly or through a healthcare …See details»

AskBio Announces Strategic Collaboration with ReCode …

Jan 9, 2023 · ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver. The SORT LNP platform …See details»

ReCode Announces Two Key Additions to Scientific Advisory Board

Oct 1, 2024 · ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables highly precise and targeted delivery of genetic medicines directly to the …See details»

ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study …

Jan 3, 2024 · Phase 1 study aims to evaluate safety and tolerability of a single ascending dose of RCT1100 in patients with PCD caused by mutations in the DNAI1 gene. RCT1100 is the first …See details»

ReCode Announces Two Key Additions to Scientific Advisory Board

Oct 1, 2024 · ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today …See details»

Unshackling genetic medicines byenablingdeliverybeyondtheliver

Harnessing its selective organ targeting lipid nanoparticle platform technology, ReCode Therapeutics is facilitating precision delivery of genetic cargos directly to their intended organs …See details»

ReCode Therapeutics to Present at Morgan Stanley 20

Sep 6, 2022 · ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs …See details»

Intellia Therapeutics and ReCode Therapeutics Announce Strategic ...

Feb 15, 2024 · ReCode will lead the subsequent preclinical and clinical development. ReCode will also lead worldwide commercialization for certain programs arising from the collaboration. …See details»

Texas Comptroller’s Office Releases Study on Organized Retail …

3 days ago · If ORT trends indicate a need, consider creating an organization to combat ORT modeled after or housed under the Texas Financial Crimes Intelligence Center. Finding 2: …See details»

ReCode Therapeutics Announces Strategic Collaboration with …

Jan 9, 2023 · ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs …See details»

Science - ReCode Therapeutics

Our selective organ targeting (SORT) lipid nanoparticles (LNPs) are engineered with a distinct fifth lipid to help the body “sort” and direct the LNPs to targeted organs with the ability to bypass …See details»

linkstock.net © 2022. All rights reserved